To examine whether the menstrual or monophasic oral contraceptive cycle phases affect submaximal (oxygen uptake (trueV˙O2) kinetics, maximal lactate steady‐state (MLSS)) and maximal (trueV˙O2max, time‐to‐exhaustion (TTE)) responses to exercise in healthy, active women. During the mid‐follicular or inactive‐pill phase and the mid‐luteal or active‐pill phase of the respective menstrual or oral contraceptive cycle, 15 non‐oral contraceptive users (mean and standard deviation (SD) (±): 27 ± 6 years; 171 ± 5 cm; 65 ± 7 kg) and 15 monophasic oral contraceptive users (24 ± 4 years; 169 ± 10 cm; 68 ± 10 kg) performed: one trueV˙O2 kinetics test; one ramp‐incremental test; two to three 30‐minute constant‐load cycling trials to determine the power output corresponding to MLSS (MLSSp), followed by a TTE trial. The phase of the menstrual or oral contraceptive cycle did not affect the time constant of the trueV˙O2 kinetics response (τtrueV˙O2) (mid‐follicular, 20 ± 5 seconds and mid‐luteal, 18 ± 3 seconds; inactive‐pill, 22 ± 8 seconds and active‐pill, 23 ± 6 seconds), trueV˙O2max (mid‐follicular, 3.06 ± 0.32 L min−1 and mid‐luteal, 3.00 ± 0.33 L min−1; inactive‐pill, 2.87 ± 0.39 L min−1 and active‐pill, 2.87 ± 0.45 L min−1), MLSSp (mid‐follicular, 181 ± 30 W and mid‐luteal, 182 ± 29 W; inactive‐pill, 155 ± 26 W and active‐pill, 155 ± 27 W), and TTE (mid‐follicular, 147 ± 42 seconds and mid‐luteal, 128 ± 54 seconds; inactive‐pill, 146 ± 70 seconds and active‐pill, 139 ± 77 seconds) (P > .05). The rate of perceived exertion (RPE) at minute 30 of the MLSSp trials was greater in the mid‐follicular phase (6.2 ± 1.5) compared with the mid‐luteal phase (5.3 ± 1.4) for non‐oral contraceptive users (P = .022). The hormonal fluctuations between the menstrual and oral contraceptive cycle phases had no detectable effects on submaximal and maximal exercise performance, even when RPE differed.

No abstract

The objective was to examine whether the menstrual or monophasic oral contraceptive cycle phases affect microvascular responsiveness of the lower limb in healthy, active women. During the follicular or inactive-pill phase and the luteal or active-pill phase of the menstrual or oral contraceptive cycle, respectively, 15 non-oral contraceptive users (mean ± SD; 27 ± 6 years of age) and 15 monophasic oral contraceptive users (24 ± 4 years of age) underwent a lower-limb vascular occlusion test (5 min baseline, 5 min occlusion and 8 min post cuff release). Menstrual cycle phases were verified using an ovulation test. Vascular responsiveness was assessed by calculating the near-infrared spectroscopy-derived muscle oxygen saturation (StO 2) reperfusion slope (slope 2 StO 2) and the post occlusion StO 2 area under the curve (StO 2AUC) of the tibialis anterior muscle. There were no differences in the reperfusion slope (as a percentage per second; follicular, 1.18 ± 0.48; luteal, 1.05 ± 0.48, inactive-pill, 0.95 ± 0.23; and active-pill, 0.87 ± 0.36; P = 0.09) and area under the curve (as a product of the percentage and seconds; follicular, 1067 ± 562; luteal, 918 ± 414, inactive-pill, 945 ± 702; and active-pill, 750 ± 519; P = 0.09) between the phases of the menstrual or oral contraceptive cycle, regardless of pill generation. The duration of oral contraceptive use was not associated with changes in slope 2 StO 2 (r = 0.02, P = 0.94) or StO 2AUC (r = −0.34, P = 0.22) between cycle phases. In conclusion, vascular responsiveness remained unchanged between the early follicular and mid-luteal phases of the menstrual cycle and the inactive-pill and active-pill phases of the oral contraceptive cycle.